Harrow (NASDAQ:HROW - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. On average, analysts expect Harrow to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Harrow Stock Performance
Shares of NASDAQ:HROW traded up $2.44 during midday trading on Wednesday, reaching $48.24. The company's stock had a trading volume of 399,974 shares, compared to its average volume of 495,576. The firm has a market capitalization of $1.71 billion, a PE ratio of -50.78 and a beta of 0.76. Harrow has a twelve month low of $7.60 and a twelve month high of $59.23. The stock has a fifty day moving average of $46.70 and a 200 day moving average of $30.57. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18.
Analysts Set New Price Targets
HROW has been the topic of a number of research reports. Lake Street Capital increased their price objective on shares of Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Craig Hallum increased their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Finally, B. Riley reissued a "buy" rating and set a $50.00 price target on shares of Harrow in a report on Thursday, August 29th.
Read Our Latest Stock Analysis on Harrow
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
